18 results
8-K
SHPH
Shuttle Pharmaceuticals Holdings Inc
22 May 24
Regulation FD Disclosure
4:15pm
will not be deemed an admission as to the materiality of any information of the information contained in this Item 7.01, including Exhibit 99.1.
Forward-Looking
8-K
SHPH
Shuttle Pharmaceuticals Holdings Inc
29 Apr 24
Other Events
10:05am
, regardless of any general incorporation language in such filings. This Current Report on Form 8-K will not be deemed an admission as to the materiality
8-K
SHPH
Shuttle Pharmaceuticals Holdings Inc
23 Apr 24
Other Events
4:36pm
Report on Form 8-K will not be deemed an admission as to the materiality of any information of the information contained in this Item 8.01, including
424B3
SHPH
Shuttle Pharmaceuticals Holdings Inc
22 Mar 24
Prospectus supplement
6:07am
the materiality of this change in presentation on prior period consolidated financial statements in accordance with SEC Staff Accounting Bulletin No. 99 … , “Materiality,” (ASC Topic 250, Accounting Changes and Error Corrections). Based on this assessment, the Company concluded that these error
8-K
szrxwwfu0 eh50bhd
13 Feb 24
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering
8:00am
8-K
qzkz1h6mz
8 Jan 24
Shuttle Pharmaceuticals Receives FDA approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
9:05am
8-K
airz byxc8yhylzh6tm
25 Sep 23
Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
9:00am
424B3
qie9l61vf19 vk
24 Aug 23
Prospectus supplement
2:00pm
8-K
ob5ajkvt9ab5zc4i9yw
7 Dec 22
Regulation FD Disclosure
4:10pm
S-1/A
EX-1.1
xn1q2ii
23 Jun 22
IPO registration (amended)
5:24pm
S-1
EX-10.1
gc6m wsmm0
3 Jun 22
IPO registration
5:32pm
DRS
EX-10.1
4bwf5 bt69a
16 Sep 19
Draft registration statement
12:00am
- Prev
- 1
- Next